Showing 461-470 of 1150 results for "".
Case Report: Pityriasis Versicolor: Using the Wood's Lamp in Diagnosis; Residents of Distinction Honored
https://practicaldermatology.com/youngmd-connect/resident-resource-center/case-report-pityriasis-versicolor-using-the-woods-lamp-in-diagnosis-residents-of-distinction-honored/21011/Pipeline and Potential Roles for GLP-1RAs in Dermatology
https://practicaldermatology.com/issues/novemberdecember-2025/pipeline-and-potential-roles-for-glp-1ras-in-dermatology/48898/Having reviewed the mechanism of action and current roles in medicine for glucagon-like peptide 1 receptor agonists (GLP-1RAs), we now can discuss therapies in this class currently under investigation for management of dermatologic disease.Improving Your After-Tax Financial Efficiency
https://practicaldermatology.com/topics/practice-management/improving-your-after-tax-financial-efficiency/20587/Two strategies for recapturing dollars left on the table.Vitamin D and Psoriasis
https://practicaldermatology.com/topics/practice-management/vitamin-d-and-psoriasis/21470/New findings suggest a relationship between psoriasis and vitamin D deficiency, but larger details are still unknown.Dupilumab For the Management of Pembrolizumab-induced Rash: A Case Report
https://practicaldermatology.com/youngmd-connect/resident-resource-center/dupilumab-for-the-management-of-pembrolizumab-induced-rash-a-case-report/23841/"Psleep": Psoriasis and Sleep
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/psleep-psoriasis-and-sleep/29075/The “invisible” impacts of psoriasis are those not directly seen on examination. These include itch, pain, fatigue and sleep dysfunction, which may be improved by our systemic therapies. However, there is a gap between the patients’ reporting of these experienced invisible impacts and their physiciaIs Irritable Bowel Linked to Irritable Skin?
https://practicaldermatology.com/columns/clinical-focus-1/is-irritable-bowel-linked-to-irritable-skin/23324/Exploring irritable bowel syndrome’s link to dermatologic conditions.Biosimilar Medicines in Dermatology: Key Aspects
https://practicaldermatology.com/topics/psoriasis/biosimilar-medicines-in-dermatology-key-aspects/22929/After the recent enactment of a specific approval pathway for biosimilars and publication of the first draft guidelines on biosimilar product development by the FDA, biosimilars are expected to be available in the US soon.The Microbiome in Atopic Dermatitis: Where Are We Now?
https://practicaldermatology.com/topics/atopic-dermatitis/the-microbiome-in-atopic-dermatitis-where-are-we-now/23746/It seems increasingly likely that microbes will play a central role in understanding AD and its treatments.The Excoriated and Bleeding Edge: Updates in Eczema for the Clinician
https://practicaldermatology.com/topics/general-topics/the-excoriated-and-bleeding-edge-updates-in-eczema-for-the-clinician/21469/Atopic dermatitis continues to present treatment challenges, but a steady juggling of four main components—moisturization, antibiotics, anti-inflammatory, and antipruritics— help to maximize control of the disease.